GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate for a hefty $1.2 billion upfront. That drug in question is ...

GSK agreed to buy an experimental medicine from a Cambridge biotech for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies. The treatment ...

GSK will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British pharma giant said Wednesday that it will pay ...

May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...

British pharmaceutical company GSK (NYSE:GSK) to acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, for as much as $2 billion in cash. Under the agreement, GSK will pay $1.2 billion ...

Alyson Hannigan, Ask2BSure spokesperson, actress, and mom, stars in an Ask2BSure campaign video to raise awareness about meningitis and vaccination amongst parents of teens and young adults.

GSK to pay $1.2 billion upfront and up to $800 million in milestones for efimosfermin, a Phase 3-ready liver disease drug. Efimosfermin showed fibrosis improvement, MASH resolution, and HbA1c ...

Investors might want to bet on GSK (GSK), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...